Clinical Trial

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
Protocol Amendment History 4 changes
notable Trial sites reduced: 40 -> 35 locations 2026-08-04
notable Primary completion pushed: 2029-07-05 -> 2029-08-06 2026-08-04
minor Completion pushed: 2029-07-05 -> 2029-08-06 2026-08-04
notable Trial sites reduced: 45 -> 40 locations 2026-07-01
Trial Details
NCT Number NCT07284745
Lead Sponsor Bristol-Myers Squibb
Conditions Irritability Associated With Autism Spectrum Disorder
Enrollment 176 participants
Start Date 2026-09-11
Primary Completion 2029-08-06 (estimated)
Study Completion 2029-08-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-03